BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Long-Term Efficacy Data From the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated With ABRAXANE Vs. Solvent-Based Paclitaxel to Be Reported

  The results from the 1,206 patient study found that ABRAXANE demonstrated a significantly higher disease-free survival rate, a secondary efficacy endpoint, in high risk early breast cancer patients when compared to conventional solvent-based paclitaxel.

  December 7, 2017

   · 

  14 min read
• ABIVAX to Present in Plenary Session at the 8th International Conference on HIV Persistence During Therapy

  The conference will take place December 12-15 at the Marriott Biscayne Bay Resort in Miami, FL.

  December 7, 2017

   · 

  1 min read
• Business

  Generex Announces Collaboration With Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China

  Shenzhen BioScien will pay Generex a non-refundable, up-front license fee of $700,000 USD.

  December 7, 2017

   · 

  4 min read
• Business

  BioPharmX Reports Third Quarter 2018 Financial Results

  Total operating expenses for the third quarter of 2018 were $3.7M, compared with total operating expenses of $4.2M in the prior fiscal year’s third quarter.

  December 7, 2017

   · 

  18 min read
• Business

  Disney Board Elects Oracle’s Safra Catz and Illumina’s Francis A. deSouza as Directors

  The elections of Ms. Catz and Mr. deSouza are effective February 1, 2018.

  December 7, 2017

   · 

  3 min read
• Business

  Enzo Biochem Reports Improved Operating Results First Quarter Results

  Total revenue in the first fiscal quarter increased to $27.7 million, or 5%, from $26.3 million in the prior year period.

  December 7, 2017

   · 

  11 min read
• Drug Development

  Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy With Zytiga at San Antonio Breast Cancer Symposium (SABCS)

  The presentation data indicates that PCM-075 in combination with anti-androgen, abiraterone acetate, are synergistic in inducing cell death within an AR+ TNBC cell line.

  December 7, 2017

   · 

  6 min read
• Biotech Beach

  City of Hope Physicians Present New CAR-T Cell Therapy Study Results and Other Research at 2017 American Society of Hematology Annual Meeting

  The trials, presented by City of Hope physicians and researchers, could ultimately lead to innovative therapeutic approaches that improve treatment options and quality of life for patients with blood cancers and other diseases.

  December 7, 2017

   · 

  8 min read
• 

  Business

  Invacare Takes an Ax to 110 Jobs in North America

  The cuts are expected to generate approximately $8.5 million in annualized pre-tax savings.

  December 7, 2017

   · 

  4 min read
• Biotech Bay

  Syner-Med Improves Sales Execution With Veeva OpenData

  Veeva OpenData and Veeva CRM are part of Veeva Commercial Cloud, a suite of applications that Syner-Med is adopting to establish a foundation for their commercial operations as the company launches more new products over the next two years.

  December 7, 2017

   · 

  4 min read